379
Participants
Start Date
June 29, 2021
Primary Completion Date
March 31, 2023
Study Completion Date
March 31, 2023
Screening
After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
Antwerp University Hospital UZA, Edegem
University of Basel, Basel
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center HICCC, New York
Charite Universitatsmedizin Berlin, Berlin
Albert P. Hirdt D.O. P.C., New Paltz
Roswell Park Cancer Center, Buffalo
Duke University: Duke Allergy Asthma Airway Center, Durham
Medizinische Hochschule Hannover, Dept. of Dermatology and Allergy, Hanover
CHU Toulouse, Toulouse
Clinical Research Center of Alabama, Birmingham
Azienda Ospedaliera Universitaria Integrata Verona, Verona
Hospital Virgen del Valle, Toledo
Bernstein Clinical Research Center, LLC, Cincinnati
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
Pitié-Salpêtrière Hospital, Paris
Klinik fuer Dermatologie und Allergologie, München
AOU San Giovanni di Dio e Ruggi d'Aragona University of Salerno, Salerno
Scripps Clinic Carmel Valley, San Diego
Brigham and Women's Hospital, Boston
University Hospital of Leicester, Leicester
Guy's and St Thomas' NHS Foundation Trust, London
University Hospitals Plymouth NHS Trust, Plymouth
Lead Sponsor
Blueprint Medicines Corporation
INDUSTRY